RYTM Stock Analysis: Rhythm Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 7.935m USD | 12M Return: 10.9% | US76243J1051 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 73.5M
Qual. Beats: 0
Rev. Trend: 99.4%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 8.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company developing treatments for rare neuroendocrine diseases, with a primary focus on genetic and syndromic forms of obesity. Its lead product, IMCIVREE (setmelanotide), is a melanocortin-4 receptor (MC4R) agonist approved for several ultra-rare conditions including POMC, LEPR deficiency obesity, Bardet-Biedl and Alström syndromes, Prader-Willi syndrome, and hypothalamic obesity. The company is headquartered in Boston, Massachusetts, was founded in 2008 (formerly known as Rhythm Metabolic, Inc.), and trades on NASDAQ as RYTM within the Biotechnology sub-industry.
The companys pipeline extends IMCIVREEs label into additional obesity indications (Phase 3) and includes earlier-stage assets such as the oral MC4R agonist bivamelagon (Phase 2) and the next-generation peptide agonist RM-718 (Phase 1). Rhythm operates within the rare disease biopharma segment, where therapies typically target small patient populations and frequently qualify for orphan drug designation, supporting extended market exclusivity and premium pricing.
- IMCIVREE revenue accelerates on expanded rare obesity approvals
- Phase 3 hypothalamic obesity data could unlock label expansion
- Oral bivamelagon pipeline advances target broader MC4R market
| Net Income: -205.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.34 > 0.02 and ΔFCF/TA -5.51 > 1.0 |
| NWC/Revenue: 126.3% < 20% (prev 147.9%; Δ -21.67% < -1%) |
| CFO/TA -0.34 > 3% & CFO -149.5m > Net Income -205.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.6m) vs 12m ago 7.71% < -2% |
| Gross Margin: 89.00% > 18% (prev 89.25%; Δ -0.25% > 0.5%) |
| Asset Turnover: 59.24% > 50% (prev 41.93%; Δ 17.31% > 0%) |
| Interest Coverage Ratio: -10.05 > 6 (EBIT TTM -185.8m / Interest Expense TTM 18.5m) |
| A: 0.69 (Total Current Assets 426.6m - Total Current Liabilities 123.6m) / Total Assets 437.3m |
| B: -3.33 (Retained Earnings -1.46b / Total Assets 437.3m) |
| C: -0.46 (EBIT TTM -185.8m / Avg Total Assets 405.0m) |
| D: 0.99 (Book Value of Equity 217.3m / Total Liabilities 220.0m) |
| Altman-Z'' = -8.36 = D |
| DSRI: 1.01 (Receivables 40.4m/26.1m, Revenue 239.9m/156.3m) |
| GMI: 1.00 (GM 89.25% / 89.00%) |
| AQI: 0.78 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 1.54 (Revenue 239.9m / 156.3m) |
| TATA: -0.13 (NI -205.3m - CFO -149.5m) / TA 437.3m) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of August 24, 2026, the stock is trading at USD 110.00 with a total of 506,215 shares traded. Over the past week, the price has changed by -4.75%, over one month by +7.15%, over three months by +22.47% and over the past year by +10.89%.
Current recommended Stop Loss: 103.80 (which is 5.6% or 1.3 ATR below the current price).
Rhythm Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy RYTM.
- StrongBuy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 141.5 | 28.7% |
P/S = 33.0746
P/B = 77.2541
Revenue TTM = 239.9m USD
EBIT TTM = -185.8m USD
EBITDA TTM = -184.7m USD
Long Term Debt = 2.98m USD (estimated: total debt 3.68m - short term 703k)
Short Term Debt = 703k USD (from shortTermDebt, last quarter)
Debt = 3.68m USD (from shortLongTermDebtTotal, last quarter) (leases 3.68m already included)
Net Debt = -327.2m USD (calculated: Debt 3.68m - CCE 330.9m)
Enterprise Value = 7.61b USD (7.94b + Debt 3.68m - CCE 330.9m)
Interest Coverage Ratio = -10.05 (Ebit TTM -185.8m / Interest Expense TTM 18.5m)
EV/FCF = -50.56x (Enterprise Value 7.61b / FCF TTM -150.5m)
FCF Yield = -1.98% (FCF TTM -150.5m / Enterprise Value 7.61b)
FCF Margin = -62.72% (FCF TTM -150.5m / Revenue TTM 239.9m)
Net Margin = -85.59% (Net Income TTM -205.3m / Revenue TTM 239.9m)
Gross Margin = 89.00% ((Revenue TTM 239.9m - Cost of Revenue TTM 26.4m) / Revenue TTM)
Gross Margin QoQ = 87.47% (prev 88.09%)
Tobins Q-Ratio = 17.40 (Enterprise Value 7.61b / Total Assets 437.3m)
Interest Expense / Debt = 501.9% (Interest Expense 18.5m / Debt 3.68m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -146.8m (EBIT -185.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.45 (Total Current Assets 426.6m / Total Current Liabilities 123.6m)
Debt / Equity = 0.02 (Debt 3.68m / totalStockholderEquity, last quarter 217.3m)
Debt / EBITDA = 1.77 (negative EBITDA) (Net Debt -327.2m / EBITDA -184.7m)
Debt / FCF = 2.17 (negative FCF - burning cash) (Net Debt -327.2m / FCF TTM -150.5m)
Total Stockholder Equity = 255.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.70% (Net Income -205.3m / Total Assets 437.3m)
RoE = -80.48% (Net Income TTM -205.3m / Total Stockholder Equity 255.2m)
RoCE = -71.98% (EBIT -185.8m / Capital Employed (Equity 255.2m + L.T.Debt 2.98m))
RoIC = -48.54% (negative operating profit) (NOPAT -146.8m / Invested Capital 302.4m)
WACC = 7.89% (E(7.94b)/V(7.94b) * Re(7.89%) + (debt cost/tax rate unavailable))
Discount Rate = 7.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.64 | Cagr: 6.02%
[DCF] Fair Price = unknown (Cash Flow -150.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.73 | # QB: 0
Revenue Correlation: 99.43 | Revenue CAGR: 58.58% | SUE: 0.95 | # QB: 2
EPS current Quarter (2026-09-30): EPS=-0.75 | Chg30d=+8.24% | Revisions=+18% | Analysts=11
EPS current Year (2026-12-31): EPS=-3.07 | Chg30d=+5.29% | Revisions=+36% | GrowthEPS=+1.3% | GrowthRev=+65.3%
EPS next Year (2027-12-31): EPS=-0.61 | Chg30d=+10.80% | Revisions=-18% | GrowthEPS=+80.1% | GrowthRev=+78.9%
[Analyst] Revisions Ratio: +15% (up=14, down=10)